WallStSmart

Ardent Health Partners, Inc. (ARDT)vsDaVita HealthCare Partners Inc (DVA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

DaVita HealthCare Partners Inc generates 115% more annual revenue ($13.84B vs $6.43B). DVA leads profitability with a 5.7% profit margin vs 2.1%. ARDT trades at a lower P/E of 11.0x. DVA earns a higher WallStSmart Score of 67/100 (B-).

ARDT

Hold

47

out of 100

Grade: D+

Growth: 4.7Profit: 5.0Value: 6.7Quality: 6.5
Piotroski: 4/9Altman Z: 2.05

DVA

Strong Buy

67

out of 100

Grade: B-

Growth: 7.3Profit: 6.5Value: 5.3Quality: 5.5
Piotroski: 3/9Altman Z: 1.22
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for ARDT.

DVASignificantly Overvalued (-15.7%)

Margin of Safety

-15.7%

Fair Value

$124.67

Current Price

$238.86

$114.19 premium

UndervaluedFair: $124.67Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ARDT2 strengths · Avg: 10.0/10
P/E RatioValuation
11.0x10/10

Attractively priced relative to earnings

Price/BookValuation
1.2x10/10

Reasonable price relative to book value

DVA4 strengths · Avg: 9.0/10
Return on EquityProfitability
81.0%10/10

Every $100 of equity generates 81 in profit

Debt/EquityHealth
-17.5010/10

Conservative balance sheet, low leverage

PEG RatioValuation
0.748/10

Growing faster than its price suggests

EPS GrowthGrowth
43.5%8/10

Earnings expanding 43.5% YoY

Areas to Watch

ARDT4 concerns · Avg: 3.0/10
Market CapQuality
$1.50B3/10

Smaller company, higher risk/reward

Return on EquityProfitability
7.7%3/10

ROE of 7.7% — below average capital efficiency

Profit MarginProfitability
2.1%3/10

2.1% margin — thin

Debt/EquityHealth
1.323/10

Elevated debt levels

DVA3 concerns · Avg: 2.7/10
Profit MarginProfitability
5.7%3/10

5.7% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Altman Z-ScoreHealth
1.222/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : ARDT

The strongest argument for ARDT centers on P/E Ratio, Price/Book.

Bull Case : DVA

The strongest argument for DVA centers on Return on Equity, Debt/Equity, PEG Ratio. PEG of 0.74 suggests the stock is reasonably priced for its growth.

Bear Case : ARDT

The primary concerns for ARDT are Market Cap, Return on Equity, Profit Margin. Thin 2.1% margins leave little buffer for downturns.

Bear Case : DVA

The primary concerns for DVA are Profit Margin, Piotroski F-Score, Altman Z-Score.

Key Dynamics to Monitor

DVA carries more volatility with a beta of 0.88 — expect wider price swings.

ARDT is growing revenue faster at 7.0% — sustainability is the question.

DVA generates stronger free cash flow (219M), providing more financial flexibility.

Monitor MEDICAL CARE FACILITIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

DVA scores higher overall (67/100 vs 47/100). Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Ardent Health Partners, Inc.

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Ardent Health Partners, Inc., headquartered in Nashville, Tennessee, is a prominent healthcare organization dedicated to delivering high-quality, patient-centered care across its extensive network of hospitals and outpatient facilities. With a strong emphasis on innovation and operational excellence, Ardent integrates a diverse array of acute care services and customized healthcare solutions to meet the unique needs of the communities it serves. Backed by a robust financial position and a strategic growth agenda, the company is well-positioned to expand healthcare access and enhance patient outcomes amid the continually evolving healthcare landscape.

Visit Website →

DaVita HealthCare Partners Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

DaVita Inc. provides kidney dialysis services through a network of outpatient dialysis centers in the United States.

Want to dig deeper into these stocks?